The plasmids used in the present study were pLenti CMV-BRAF V600E and pLenti-CMV-GNA11 Q209L, which subcloned human BRAFV600E or GNA11Q209L cDNA into pLenti CMV Hygro DEST (a gift from Eric Campeau & Paul Kaufman (Addgene plasmid #17454)37 (link). LentiCas9-Blast was a gift from Feng Zhang (Addgene plasmid #52962; http://n2t.net/addgene:52962 ; RRID:Addgene_52962)38 (link). Lentivirus particles were produced as previously described39 (link).
The Arp2/3 inhibitor, CK-689, and the PI3K inhibitor, LY294002, were purchased from Merck KGaA (Darmstadt, Germany). The AKT inhibitor, MK-2206, was obtained from Active Biochemicals (Wan Chai, Hong Kong). The RSK inhibitors, BI-D1870 and LJH685, were supplied by BioVision (BioVision, Milpitas, CA, USA) and Cayman Chemical (Cayman Chemical, Ann Arbor, MI, USA), respectively. ALW II-41-27 was purchased from MedChemExpress (Monmouth Junction, NJ, USA).
The Arp2/3 inhibitor, CK-689, and the PI3K inhibitor, LY294002, were purchased from Merck KGaA (Darmstadt, Germany). The AKT inhibitor, MK-2206, was obtained from Active Biochemicals (Wan Chai, Hong Kong). The RSK inhibitors, BI-D1870 and LJH685, were supplied by BioVision (BioVision, Milpitas, CA, USA) and Cayman Chemical (Cayman Chemical, Ann Arbor, MI, USA), respectively. ALW II-41-27 was purchased from MedChemExpress (Monmouth Junction, NJ, USA).
Free full text: Click here
